查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1933320

细胞疗法市场规模、占有率、成长及全球产业分析：依类型、应用、区域洞察及预测（2026-2034 年）

Cell Therapy Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 210 Pages | 商品交期: 请询问到货日

价格

细胞疗法市场成长驱动因子

受技术进步、先进细胞疗法的日益普及以及针对肿瘤和罕见疾病治疗需求不断增长的推动，全球细胞疗法市场正经历快速增长。预计该市场规模将在 2025 年达到 88.8 亿美元，2026 年达到 123.4 亿美元，到 2034 年达到 1903.6 亿美元，预测期内复合年增长率 (CAGR) 高达 40.78%。

细胞疗法是一种治疗方法，将自体或来自其他捐赠者的活细胞输注给患者，以治疗或预防疾病。 这包括源自基因工程改造的T细胞、自然杀手细胞和诱导多能干细胞（iPS细胞）的疗法，这些疗法能够恢復正常细胞功能、清除病变细胞并再生受损组织。该市场由诺华公司、吉利德科学公司和百时美施贵宝公司等大型生物製药公司引领，并受益于强大的研发管线、丰富的产品线和全球布局。

市场动态

市场驱动因素

庞大的未满足医疗需求，尤其是在肿瘤学和罕见遗传疾病领域，是推动市场发展的关键因素。许多罕见疾病（约占所有疾病的95%）缺乏FDA核准的治疗方法，因此对个人化细胞疗法的需求日益增长。镰状细胞疾病患者数量的不断增长（据估计，2021年全球患者人数为774万人）进一步推动了对标靶疗法的需求。 CAR-T 和基因修饰 T 细胞疗法的快速临床进展和不断扩大的批准正在推动市场成长。

市场限制因子

安全问题和临床风险，例如肿瘤形成、免疫排斥、移植物抗宿主疾病 (GVHD)、细胞激素释放症候群 (CRS) 和神经毒性，限制了市场扩张。这些风险需要专门的医院基础设施，并将实施限制在经过认证的机构。例如，Yescarta（吉利德科学公司）在约 32% 的大 B 细胞淋巴瘤患者中出现了 3 级或更高等级的神经毒性。

市场机会

异基因细胞疗法的出现提供了即用型解决方案，实现了规模化、降低成本并加快了治疗启动。技术进步和对肿瘤学、自体免疫疾病和神经系统疾病应用领域投资的增加，带来了巨大的成长机会。 例如，2025年6月，Allogene Therapeutics公布了ALLO-316治疗晚期肾细胞癌的I期临床试验的良好数据。

市场挑战

高昂的治疗费用仍然是一项重大挑战。 CAR-T疗法，例如Yescarta，每个疗程的费用约为537,592美元，此外还有住院和治疗后护理费用。这限制了患者获得治疗的机会，尤其是在医疗预算有限的新兴市场。

市场趋势

一个显着的趋势是细胞疗法的应用范围从血液系统恶性肿瘤扩展到实体肿瘤。各公司正在开发双重和三重CAR-T细胞疗法，以克服抗原逃脱并提高实体瘤的疗效。 2024年2月，Iovance Biotherapeutics的AMTAGVI（lifileucel）获得FDA批准用于治疗晚期黑色素瘤，显示监管机构对肿瘤领域的创新疗法给予了支持。

市场区隔分析

依疗法分类：

  • CAR-T 细胞疗法将保持其主导地位，到 2026 年将占 98.78% 的市场占有率，这主要得益于监管部门的批准、市场接受度的提高以及对临床研发管线的投资。
  • 其他疗法包括 TCR-T 细胞疗法和自然杀手 (NK) 细胞疗法。

依产品分类：

  • Yescarta 凭藉其庞大的患者群体、优惠的报销体係以及遍布全球的 570 多家授权治疗中心，在市场上占领先地位。
  • Abecma 预计在预测期内将以 14.66% 的复合年增长率成长。

依适应症划分：

  • 在大量已批准的产品、不断扩大的临床试验和投资的推动下，肿瘤领域将在2025年占100%的市场占有率。
  • 其他适应症的市占率有限，预计到2032年将达到1,000万美元。

依最终使用者划分：

  • 由于拥有专业的医疗基础设施和完善的医保报销机制，医院和诊所将继续保持领先地位，预计到2026年将占55.43%的市场占有率。
  • 专科诊所预计将以42.11%的复合年增长率成长。

区域展望

  • 北美：最大的市场，2025 年市场规模为 42.2 亿美元，2026 年为 58.8 亿美元。这主要得益于已上市产品、强大的临床研发管线以及阿斯特捷利康 2025 年在美国研发和生产设施方面投资 5,000 万美元。美国将成为最大的贡献者，2026 年市场规模将达到 54.8 亿美元。
  • 欧洲：2025 年市场规模将达到 23.9 亿美元，年复合成长率 (CAGR) 为 36.55%。 2026年，英国和德国分别贡献了5.3亿美元和7.9亿美元。 亚太地区：预计2025年市场规模将达到14.5亿美元，其中日本（4.3亿美元）、中国（7.7亿美元）和印度（1.3亿美元）将是2026年的主要市场。 拉丁美洲：预计2025年市场规模将达4.8亿美元，但由于基础建设限制，普及率有限。 中东和非洲：预计2025年海湾合作委员会（GCC）市场规模将达1.9亿美元，成长速度放缓。

目录

第一章：引言

第二章：摘要整理

第三章：市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机遇
  • 市场趋势

第四章：关键考虑因素

  • 概述：细胞疗法在新疾病适应症的进展
  • 主要国家的监管环境
  • 市场技术进步
  • 主要公司的新产品发布
  • 主要公司的研发管线分析
  • 主要产业趋势（併购、合作、新产品发表）等等）
  • 市场格局中的定价与报销趋势
  • 製造与供应链洞察
  • 市场投资与融资趋势

第五章：全球细胞疗法市场分析、洞察与预测（2021-2034）

  • 市场分析、洞察与预测 - 依疗法分类
    • CAR-T 细胞疗法
    • TCR-T 细胞疗法
    • 自然杀手 (NK) 细胞疗法
    • 其他疗法
  • 市场分析、洞察与预测 - 依产品分类
    • Kymriah
    • Yescata
    • Tecartas
    • Bryanji
    • Abekuma
    • Kalvikti
    • 其他疗法
  • 市场分析、洞察与预测 - 依适应症
    • 肿瘤科
    • 其他
  • 市场分析、洞察与预测 - 依最终用户划分
    • 医院和诊所
    • 专科诊所
    • 其他
  • 市场分析、洞察与预测 - 依地区划分
    • 北美
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲

第六章 北美细胞治疗市场分析、洞察与预测（2021-2034）

  • 依国家划分
    • 美国
    • 加拿大

第七章：欧洲细胞治疗市场分析、洞察与预测2021-2034

  • 依国家划分
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 斯堪的纳维亚半岛
    • 欧洲其他地区

第八章 亚太细胞治疗市场分析、洞察与预测（2021-2034）

  • 依国家划分
    • 中国
    • 日本
    • 印度
    • 澳大利亚
    • 东南亚
    • 亚太其他地区

第九章 拉丁美洲细胞治疗市场分析、洞察与预测（2021-2034）

  • 依国家/地区
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地区

第十章 中东与非洲细胞疗法市场分析、洞察与预测（2021-2034）

  • 依国家划分
    • 海湾合作委员会 (GCC)
    • 南非
    • 中东和非洲其他地区

第十一章：竞争分析

  • 全球市占率分析（2025）
  • 公司简介
  • Novartis AG
  • Gilead Sciences, Inc.
  • Bristol Myers Squibb Company
  • Johnson &Johnson
  • Vertex Pharmaceuticals Incorporated
  • Bayer AG
  • Adaptimmune
  • IOVANCE Biotherapeutics, Inc.
  • F. Hoffmann-La Roche Ltd
  • Fate Therapeutics
Product Code: FBI114224

Growth Factors of cell therapy Market

The global cell therapy market is experiencing rapid growth, driven by technological advancements, increasing adoption of advanced cellular therapies, and rising demand for treatments targeting oncology and rare diseases. The market was valued at USD 8.88 billion in 2025, projected to grow to USD 12.34 billion in 2026, and is expected to reach USD 190.36 billion by 2034, reflecting a robust CAGR of 40.78% during the forecast period.

Cell therapy involves the administration of live cells, either autologous or allogeneic, into patients to treat or prevent diseases. These therapies include genetically engineered T-cells, natural killer cells, and induced pluripotent stem cell (iPSC)-derived therapies that restore normal cellular function, eliminate diseased cells, or regenerate damaged tissues. The market is dominated by leading biopharmaceutical players including Novartis AG, Gilead Sciences, Inc., and Bristol Myers Squibb, supported by strong R&D pipelines, wide product availability, and global reach.

Market Dynamics

Market Drivers

High unmet medical needs, particularly in oncology and rare genetic diseases, are a major driver. Many rare diseases, comprising approximately 95% of conditions, lack FDA-approved treatments, creating demand for personalized cell therapies. The increasing number of patients with conditions such as sickle cell disease, estimated at 7.74 million globally in 2021, further fuels the need for targeted therapies. Rapid clinical progress in CAR-T and engineered T-cell therapies, coupled with expanding approvals, is propelling market growth.

Market Restraints

Safety concerns and clinical risks, including tumorigenesis, immune rejection, graft-versus-host disease (GVHD), cytokine release syndrome (CRS), and neurotoxicity, restrict market expansion. These risks necessitate specialized hospital infrastructure and limit adoption to certified centers. For instance, Yescarta (Gilead Sciences, Inc.) recorded grade >=3 neurotoxicity in ~32% of patients with large B-cell lymphoma.

Market Opportunities

The emergence of allogeneic cell therapies offers off-the-shelf solutions, providing scalability, lower costs, and faster treatment initiation. Technological advancements and growing investment in oncology, autoimmune, and neurological applications provide significant growth opportunities. For example, Allogene Therapeutics reported promising Phase 1 data for ALLO-316 in June 2025, targeting advanced renal cell carcinoma.

Market Challenges

The high cost of treatment remains a significant challenge. CAR-T therapies such as Yescarta cost around USD 537,592 per regimen, with additional costs for hospitalization and post-treatment care. This limits accessibility, especially in emerging economies with constrained healthcare budgets.

Market Trends

A notable trend is the expansion of cell therapy applications beyond hematology into solid tumors. Companies are developing dual- and tri-CAR T-cells to overcome antigen escape and improve efficacy in solid cancers. In February 2024, the FDA approved AMTAGVI (lifileucel) by Iovance Biotherapeutics for advanced melanoma, demonstrating regulatory support for innovative therapies in oncology.

Segmentation Analysis

By Therapy Type:

  • CAR-T cell therapy dominates with 98.78% market share in 2026, driven by regulatory approvals, market adoption, and investment in clinical pipelines.
  • Other therapy types include TCR-T and natural killer (NK) cell therapies.

By Product:

  • Yescarta leads the market due to a large target patient base, favorable reimbursement, and global distribution through over 570 authorized treatment centers.
  • Abecma is projected to grow at 14.66% CAGR during the forecast period.

By Indication:

  • Oncology dominates with 100% market share in 2025, fueled by a high number of approved products, expanding clinical trials, and investment flow.
  • Other indications are limited, projected at USD 0.01 billion by 2032.

By End-User:

  • Hospitals & clinics dominate, holding 55.43% market share in 2026, due to specialized infrastructure and alignment with reimbursement frameworks.
  • Specialty clinics are projected to grow at 42.11% CAGR.

Regional Outlook

  • North America: Dominates with USD 4.22 billion in 2025 and USD 5.88 billion in 2026, driven by commercialized products, strong clinical pipelines, and investments such as USD 50 million by AstraZeneca in U.S. R&D and manufacturing facilities in 2025. The U.S. is the largest contributor with USD 5.48 billion in 2026.
  • Europe: Valued at USD 2.39 billion in 2025, growing at 36.55% CAGR, with the UK and Germany contributing USD 0.53 billion and USD 0.79 billion respectively in 2026.
  • Asia Pacific: Estimated at USD 1.45 billion in 2025, with key markets including Japan (USD 0.43 billion), China (USD 0.77 billion), and India (USD 0.13 billion) in 2026.
  • Latin America: Valued at USD 0.48 billion in 2025, adoption limited due to infrastructure constraints.
  • Middle East & Africa: GCC valued at USD 0.19 billion in 2025, showing slower growth.

Competitive Landscape

The market is semi-fragmented, with major players such as Novartis AG, Gilead Sciences, Bristol Myers Squibb, Johnson & Johnson, Iovance Biotherapeutics, Fate Therapeutics, and Adaptimmune. Strategies include R&D, collaborations, licensing, and clinical partnerships to strengthen market presence.

Key Developments:

  • June 2025: EMA recommended conditional marketing authorization for Zemcelpro in the EU.
  • June 2025: BMS received U.S. FDA approval for Abecma and Breyanzi CAR-T therapies.
  • April 2025: Thermo Fisher launched the Advanced Therapies Collaboration Center in California.
  • August 2024: FDA approved the first TCR therapy, afami-cel, for synovial sarcoma.
  • April 2024: India launched NexCAR19, its first homegrown CAR-T therapy.

Conclusion

The global cell therapy market is expected to grow from USD 8.88 billion in 2025 to USD 190.36 billion by 2034, at a CAGR of 40.78%. Growth is driven by the increasing adoption of CAR-T and allogeneic therapies, rising unmet medical needs in oncology and rare diseases, expanding regulatory approvals, and strategic investments by key market players. Despite high treatment costs and safety concerns, cell therapy is poised to revolutionize personalized medicine, offering curative solutions and improving patient outcomes globally.

Segmentation By Therapy Type

  • CAR-T Cell Therapy
  • TCR-T Cell Therapy
  • Natural Killer (NK) Cells
  • Others

By Product

  • Kymriah
  • Yescarta
  • Tecartus
  • Breyanzi
  • Abecma
  • Carvykti
  • Others

By Indication

  • Oncology
  • Others

By End User

  • Hospitals & Clinics
  • Specialty Clinics
  • Others

By Geography

  • North America (By Therapy Type, Product, Indication, End User, and Country)
    • U.S.
    • Canada
  • Europe (By Therapy Type, Product, Indication, End User, and Country/Sub-region)
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Therapy Type, Product, Indication, End User, and Country/Sub-region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Therapy Type, Product, Indication, End User, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Therapy Type, Product, Indication, End User, and Country/Sub-region)
    • GCC
    • South Africa
  • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Overview: Advancements in of Cell Therapy for New Disease Indications
  • 4.2. Regulatory Scenarios, By Key Countries/Regions
  • 4.3. Technological Advancements in the Market
  • 4.4. New Product Launches, By Key Players
  • 4.5. Pipeline Analysis, By Key Companies
  • 4.6. Key Industry Developments (Mergers, Acquisitions, Partnerships, Launches, and Others)
  • 4.7. Pricing & Reimbursement Landscape in the Market
  • 4.8. Manufacturing & Supply Chain Insights
  • 4.9. Investment & Funding Trends in the Market

5. Global Cell Therapy Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Therapy Type
    • 5.1.1. CAR-T Cell Therapy
    • 5.1.2. TCR-T Cell Therapy
    • 5.1.3. Natural Killer (NK) Cells
    • 5.1.4. Others
  • 5.2. Market Analysis, Insights and Forecast - By Product
    • 5.2.1. Kymriah
    • 5.2.2. Yescarta
    • 5.2.3. Tecartus
    • 5.2.4. Breyanzi
    • 5.2.5. Abecma
    • 5.2.6. Carvykti
    • 5.2.7. Others
  • 5.3. Market Analysis, Insights and Forecast - By Indication
    • 5.3.1. Oncology
    • 5.3.2. Others
  • 5.4. Market Analysis, Insights and Forecast - By End User
    • 5.4.1. Hospitals & Clinics
    • 5.4.2. Specialty Clinics
    • 5.4.3. Others
  • 5.5. Market Analysis, Insights and Forecast - Region
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Latin America
    • 5.5.5. Middle East & Africa

6. North America Cell Therapy Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Therapy Type
    • 6.1.1. CAR-T Cell Therapy
    • 6.1.2. TCR-T Cell Therapy
    • 6.1.3. Natural Killer (NK) Cells
    • 6.1.4. Others
  • 6.2. Market Analysis, Insights and Forecast - By Product
    • 6.2.1. Kymriah
    • 6.2.2. Yescarta
    • 6.2.3. Tecartus
    • 6.2.4. Breyanzi
    • 6.2.5. Abecma
    • 6.2.6. Carvykti
    • 6.2.7. Others
  • 6.3. Market Analysis, Insights and Forecast - By Indication
    • 6.3.1. Oncology
    • 6.3.2. Others
  • 6.4. Market Analysis, Insights and Forecast - By End User
    • 6.4.1. Hospitals & Clinics
    • 6.4.2. Specialty Clinics
    • 6.4.3. Others
  • 6.5. Market Analysis, Insights and Forecast - By Country
    • 6.5.1. U.S.
    • 6.5.2. Canada

7. Europe Cell Therapy Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Therapy Type
    • 7.1.1. CAR-T Cell Therapy
    • 7.1.2. TCR-T Cell Therapy
    • 7.1.3. Natural Killer (NK) Cells
    • 7.1.4. Others
  • 7.2. Market Analysis, Insights and Forecast - By Product
    • 7.2.1. Kymriah
    • 7.2.2. Yescarta
    • 7.2.3. Tecartus
    • 7.2.4. Breyanzi
    • 7.2.5. Abecma
    • 7.2.6. Carvykti
    • 7.2.7. Others
  • 7.3. Market Analysis, Insights and Forecast - By Indication
    • 7.3.1. Oncology
    • 7.3.2. Others
  • 7.4. Market Analysis, Insights and Forecast - By End User
    • 7.4.1. Hospitals & Clinics
    • 7.4.2. Specialty Clinics
    • 7.4.3. Others
  • 7.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.5.1. Germany
    • 7.5.2. U.K.
    • 7.5.3. France
    • 7.5.4. Italy
    • 7.5.5. Spain
    • 7.5.6. Scandinavia
    • 7.5.7. Rest of Europe

8. Asia Pacific Cell Therapy Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Therapy Type
    • 8.1.1. CAR-T Cell Therapy
    • 8.1.2. TCR-T Cell Therapy
    • 8.1.3. Natural Killer (NK) Cells
    • 8.1.4. Others
  • 8.2. Market Analysis, Insights and Forecast - By Product
    • 8.2.1. Kymriah
    • 8.2.2. Yescarta
    • 8.2.3. Tecartus
    • 8.2.4. Breyanzi
    • 8.2.5. Abecma
    • 8.2.6. Carvykti
    • 8.2.7. Others
  • 8.3. Market Analysis, Insights and Forecast - By Indication
    • 8.3.1. Oncology
    • 8.3.2. Others
  • 8.4. Market Analysis, Insights and Forecast - By End User
    • 8.4.1. Hospitals & Clinics
    • 8.4.2. Specialty Clinics
    • 8.4.3. Others
  • 8.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.5.1. China
    • 8.5.2. Japan
    • 8.5.3. India
    • 8.5.4. Australia
    • 8.5.5. Southeast Asia
    • 8.5.6. Rest of Asia Pacific

9. Latin America Cell Therapy Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Therapy Type
    • 9.1.1. CAR-T Cell Therapy
    • 9.1.2. TCR-T Cell Therapy
    • 9.1.3. Natural Killer (NK) Cells
    • 9.1.4. Others
  • 9.2. Market Analysis, Insights and Forecast - By Product
    • 9.2.1. Kymriah
    • 9.2.2. Yescarta
    • 9.2.3. Tecartus
    • 9.2.4. Breyanzi
    • 9.2.5. Abecma
    • 9.2.6. Carvykti
    • 9.2.7. Others
  • 9.3. Market Analysis, Insights and Forecast - By Indication
    • 9.3.1. Oncology
    • 9.3.2. Others
  • 9.4. Market Analysis, Insights and Forecast - By End User
    • 9.4.1. Hospitals & Clinics
    • 9.4.2. Specialty Clinics
    • 9.4.3. Others
  • 9.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.5.1. Brazil
    • 9.5.2. Mexico
    • 9.5.3. Rest of Latin America

10. Middle East & Africa Cell Therapy Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Therapy Type
    • 10.1.1. CAR-T Cell Therapy
    • 10.1.2. TCR-T Cell Therapy
    • 10.1.3. Natural Killer (NK) Cells
    • 10.1.4. Others
  • 10.2. Market Analysis, Insights and Forecast - By Product
    • 10.2.1. Kymriah
    • 10.2.2. Yescarta
    • 10.2.3. Tecartus
    • 10.2.4. Breyanzi
    • 10.2.5. Abecma
    • 10.2.6. Carvykti
    • 10.2.7. Others
  • 10.3. Market Analysis, Insights and Forecast - By Indication
    • 10.3.1. Oncology
    • 10.3.2. Others
  • 10.4. Market Analysis, Insights and Forecast - By End User
    • 10.4.1. Hospitals & Clinics
    • 10.4.2. Specialty Clinics
    • 10.4.3. Others
  • 10.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.5.1. GCC
    • 10.5.2. South Africa
    • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles (Overview, Products, SWOT analysis, Recent developments, strategies, financials (based on availability))
    • 11.2.1. Novartis AG
    • 11.2.2. Gilead Sciences, Inc.
    • 11.2.3. Bristol Myers Squibb Company
    • 11.2.4. Johnson & Johnson
    • 11.2.5. Vertex Pharmaceuticals Incorporated
    • 11.2.6. Bayer AG
    • 11.2.7. Adaptimmune
    • 11.2.8. IOVANCE Biotherapeutics, Inc.
    • 11.2.9. F. Hoffmann-La Roche Ltd
    • 11.2.10. Fate Therapeutics

List of Tables

  • Table 1: Global Cell Therapy Market Revenue (USD Billion) Forecast, By Therapy Type, 2021-2034
  • Table 2: Global Cell Therapy Market Revenue (USD Billion) Forecast, By Product, 2021-2034
  • Table 3: Global Cell Therapy Market Revenue (USD Billion) Forecast, By Indication, 2021-2034
  • Table 4: Global Cell Therapy Market Revenue (USD Billion) Forecast, By End User, 2021-2034
  • Table 5: Global Cell Therapy Market Revenue (USD Billion) Forecast, by Region, 2021-2034
  • Table 6: North America Cell Therapy Market Revenue (USD Billion) Forecast, By Therapy Type, 2021-2034
  • Table 7: North America Cell Therapy Market Revenue (USD Billion) Forecast, By Product, 2021-2034
  • Table 8: North America Cell Therapy Market Revenue (USD Billion) Forecast, By Indication, 2021-2034
  • Table 9: North America Cell Therapy Market Revenue (USD Billion) Forecast, By End User, 2021-2034
  • Table 10: North America Cell Therapy Market Revenue (USD Billion) Forecast, By Country, 2021-2034
  • Table 11: Europe Cell Therapy Market Revenue (USD Billion) Forecast, By Therapy Type, 2021-2034
  • Table 12: Europe Cell Therapy Market Revenue (USD Billion) Forecast, By Product, 2021-2034
  • Table 13: Europe Cell Therapy Market Revenue (USD Billion) Forecast, By Indication, 2021-2034
  • Table 14: Europe Cell Therapy Market Revenue (USD Billion) Forecast, By End User, 2021-2034
  • Table 15: Europe Cell Therapy Market Revenue (USD Billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 16: Asia Pacific Cell Therapy Market Revenue (USD Billion) Forecast, By Therapy Type, 2021-2034
  • Table 17: Asia Pacific Cell Therapy Market Revenue (USD Billion) Forecast, By Product, 2021-2034
  • Table 18: Asia Pacific Cell Therapy Market Revenue (USD Billion) Forecast, By Indication, 2021-2034
  • Table 19: Asia Pacific Cell Therapy Market Revenue (USD Billion) Forecast, By End User, 2021-2034
  • Table 20: Asia Pacific Cell Therapy Market Revenue (USD Billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 21: Latin America Cell Therapy Market Revenue (USD Billion) Forecast, By Therapy Type, 2021-2034
  • Table 22: Latin America Cell Therapy Market Revenue (USD Billion) Forecast, By Product, 2021-2034
  • Table 23: Latin America Cell Therapy Market Revenue (USD Billion) Forecast, By Indication, 2021-2034
  • Table 24: Latin America Cell Therapy Market Revenue (USD Billion) Forecast, By End User, 2021-2034
  • Table 25: Latin America Cell Therapy Market Revenue (USD Billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 26: Middle East & Africa Cell Therapy Market Revenue (USD Billion) Forecast, By Therapy Type, 2021-2034
  • Table 27: Middle East & Africa Cell Therapy Market Revenue (USD Billion) Forecast, By Product, 2021-2034
  • Table 28: Middle East & Africa Cell Therapy Market Revenue (USD Billion) Forecast, By Indication, 2021-2034
  • Table 29: Middle East & Africa Cell Therapy Market Revenue (USD Billion) Forecast, By End User, 2021-2034
  • Table 30: Middle East & Africa Cell Therapy Market Revenue (USD Billion) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Cell Therapy Market Revenue Breakdown (USD Billion, %) by Region, 2025 & 2034
  • Figure 2: Global Cell Therapy Market Value Share (%), By Therapy Type, 2025 & 2034
  • Figure 3: Global Cell Therapy Market Value Share (%), By Product, 2025 & 2034
  • Figure 4: Global Cell Therapy Market Value Share (%), By Indication, 2025 & 2034
  • Figure 5: Global Cell Therapy Market Value Share (%), By End User, 2025 & 2034
  • Figure 6: Global Cell Therapy Market Value (USD Billion), by Region, 2025 & 2034
  • Figure 7: North America Cell Therapy Market Value (USD Billion), By Therapy Type, 2025 & 2034
  • Figure 8: North America Cell Therapy Market Value Share (%), By Therapy Type, 2025
  • Figure 9: North America Cell Therapy Market Value (USD Billion), By Product, 2025 & 2034
  • Figure 10: North America Cell Therapy Market Value Share (%), By Product, 2025
  • Figure 11: North America Cell Therapy Market Value (USD Billion), By Indication, 2025 & 2034
  • Figure 12: North America Cell Therapy Market Value Share (%), By Indication, 2025
  • Figure 13: North America Cell Therapy Market Value (USD Billion), By End User, 2025 & 2034
  • Figure 14: North America Cell Therapy Market Value Share (%), By End User, 2025
  • Figure 15: North America Cell Therapy Market Value (USD Billion), By Country, 2025 & 2034
  • Figure 16: North America Cell Therapy Market Value Share (%), By Country, 2025
  • Figure 17: Europe Cell Therapy Market Value (USD Billion), By Therapy Type, 2025 & 2034
  • Figure 18: Europe Cell Therapy Market Value Share (%), By Therapy Type, 2025
  • Figure 19: Europe Cell Therapy Market Value (USD Billion), By Product, 2025 & 2034
  • Figure 20: Europe Cell Therapy Market Value Share (%), By Product, 2025
  • Figure 21: Europe Cell Therapy Market Value (USD Billion), By Indication, 2025 & 2034
  • Figure 22: Europe Cell Therapy Market Value Share (%), By Indication, 2025
  • Figure 23: Europe Cell Therapy Market Value (USD Billion), By End User, 2025 & 2034
  • Figure 24: Europe Cell Therapy Market Value Share (%), By End User, 2025
  • Figure 25: Europe Cell Therapy Market Value (USD Billion), By Country/ Sub-region, 2025 & 2034
  • Figure 26: Europe Cell Therapy Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 27: Asia Pacific Cell Therapy Market Value (USD Billion), By Therapy Type, 2025 & 2034
  • Figure 28: Asia Pacific Cell Therapy Market Value Share (%), By Therapy Type, 2025
  • Figure 29: Asia Pacific Cell Therapy Market Value (USD Billion), By Product, 2025 & 2034
  • Figure 30: Asia Pacific Cell Therapy Market Value Share (%), By Product, 2025
  • Figure 31: Asia Pacific Cell Therapy Market Value (USD Billion), By Indication, 2025 & 2034
  • Figure 32: Asia Pacific Cell Therapy Market Value Share (%), By Indication, 2025
  • Figure 33: Asia Pacific Cell Therapy Market Value (USD Billion), By End User, 2025 & 2034
  • Figure 34: Asia Pacific Cell Therapy Market Value Share (%), By End User, 2025
  • Figure 35: Asia Pacific Cell Therapy Market Value (USD Billion), By Country/ Sub-region, 2025 & 2034
  • Figure 36: Asia Pacific Cell Therapy Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 37: Latin America Cell Therapy Market Value (USD Billion), By Therapy Type, 2025 & 2034
  • Figure 38: Latin America Cell Therapy Market Value Share (%), By Therapy Type, 2025
  • Figure 39: Latin America Cell Therapy Market Value (USD Billion), By Product, 2025 & 2034
  • Figure 40: Latin America Cell Therapy Market Value Share (%), By Product, 2025
  • Figure 41: Latin America Cell Therapy Market Value (USD Billion), By Indication, 2025 & 2034
  • Figure 42: Latin America Cell Therapy Market Value Share (%), By Indication, 2025
  • Figure 43: Latin America Cell Therapy Market Value (USD Billion), By End User, 2025 & 2034
  • Figure 44: Latin America Cell Therapy Market Value Share (%), By End User, 2025
  • Figure 45: Latin America Cell Therapy Market Value (USD Billion), By Country/ Sub-region, 2025 & 2034
  • Figure 46: Latin America Cell Therapy Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 47: Middle East & Africa Cell Therapy Market Value (USD Billion), By Therapy Type, 2025 & 2034
  • Figure 48: Middle East & Africa Cell Therapy Market Value Share (%), By Therapy Type, 2025
  • Figure 49: Middle East & Africa Cell Therapy Market Value (USD Billion), By Product, 2025 & 2034
  • Figure 50: Middle East & Africa Cell Therapy Market Value Share (%), By Product, 2025
  • Figure 51: Middle East & Africa Cell Therapy Market Value (USD Billion), By Indication, 2025 & 2034
  • Figure 52: Middle East & Africa Cell Therapy Market Value Share (%), By Indication, 2025
  • Figure 53: Middle East & Africa Cell Therapy Market Value (USD Billion), By End User, 2025 & 2034
  • Figure 54: Middle East & Africa Cell Therapy Market Value Share (%), By End User, 2025
  • Figure 55: Middle East & Africa Cell Therapy Market Value (USD Billion), By Country/ Sub-region, 2025 & 2034
  • Figure 56: Middle East & Africa Cell Therapy Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 57: Global Cell Therapy Market Share (%), By Company, 2025